Zura Bio Limited (NASDAQ:ZURA) Receives Consensus Rating of “Moderate Buy” from Analysts

Zura Bio Limited (NASDAQ:ZURA) has been given an average rating of “Moderate Buy” by the six brokerages that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $10.75.

Several research firms recently commented on ZURA. Oppenheimer cut their price target on Zura Bio from $16.00 to $15.00 and set an “outperform” rating on the stock in a research note on Friday, March 20th. Wedbush restated an “outperform” rating and set a $15.00 price objective on shares of Zura Bio in a research note on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of Zura Bio in a report on Wednesday, April 8th. Finally, Chardan Capital lifted their price objective on Zura Bio from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Monday, March 23rd.

Institutional Trading of Zura Bio

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Atika Capital Management LLC bought a new position in Zura Bio during the 3rd quarter valued at $1,195,000. Suvretta Capital Management LLC increased its position in shares of Zura Bio by 12.6% in the 3rd quarter. Suvretta Capital Management LLC now owns 5,472,891 shares of the company’s stock worth $23,698,000 after purchasing an additional 611,952 shares during the last quarter. Boothbay Fund Management LLC bought a new stake in shares of Zura Bio in the 3rd quarter worth about $3,568,000. UBS Group AG raised its stake in shares of Zura Bio by 54.1% in the 4th quarter. UBS Group AG now owns 470,540 shares of the company’s stock valued at $2,466,000 after purchasing an additional 165,211 shares in the last quarter. Finally, 683 Capital Management LLC acquired a new stake in shares of Zura Bio in the 4th quarter valued at about $1,358,000. Institutional investors own 61.14% of the company’s stock.

Zura Bio Stock Performance

ZURA opened at $5.17 on Friday. Zura Bio has a twelve month low of $1.08 and a twelve month high of $7.44. The firm has a market cap of $490.53 million, a price-to-earnings ratio of -4.74 and a beta of -0.03. The company has a fifty day simple moving average of $4.45 and a 200 day simple moving average of $5.30.

Zura Bio (NASDAQ:ZURA) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.05). On average, analysts forecast that Zura Bio will post -0.76 earnings per share for the current fiscal year.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.